Terms: = Endocrine gland cancer AND HSP90AA1, ENSG00000080824, 3320, P07900, LAP2, HSPN, HSPCAL4, HSPCAL1, HSPCA, HSPC1, HSP90N, HSP90A, Hsp90, Hsp89, HSP86, FLJ31884 AND Treatment
95 results:
1. Single-cell RNA-seq analyses inform necroptosis-associated myeloid lineages influence the immune landscape of pancreas cancer.
Dong W; Zhao H; Xiao S; Zheng L; Fan T; Wang L; Zhang H; Hu Y; Yang J; Wang T; Xiao W
Front Immunol; 2023; 14():1263633. PubMed ID: 38149248
[TBL] [Abstract] [Full Text] [Related]
2. Combination therapy of tyrosine kinase inhibitor sorafenib with the hsp90 inhibitor onalespib as a novel treatment regimen for thyroid cancer.
Mortensen ACL; Berglund H; Hariri M; Papalanis E; Malmberg C; Spiegelberg D
Sci Rep; 2023 Oct; 13(1):16844. PubMed ID: 37803074
[TBL] [Abstract] [Full Text] [Related]
3. Exploring dual effects of dinutuximab beta on cell death and proliferation of insulinoma.
Karatug Kacar A
Chem Biol Drug Des; 2024 Jan; 103(1):e14368. PubMed ID: 37802653
[TBL] [Abstract] [Full Text] [Related]
4. The therapeutic effects of exosomes the first time isolated from pancreatic islet-derived progenitor cells in the treatment of pancreatic cancer.
Hasoglu I; Karatug Kacar A
Protoplasma; 2024 Mar; 261(2):281-291. PubMed ID: 37798610
[TBL] [Abstract] [Full Text] [Related]
5. Promising targetable biomarkers in pancreatic neuroendocrine tumours.
Borghesani M; Gervaso L; Cella CA; Benini L; Ciardiello D; Algeri L; Ferrero A; Valenza C; Guidi L; Zampino MG; Spada F; Fazio N
Expert Rev Endocrinol Metab; 2023; 18(5):387-398. PubMed ID: 37743651
[TBL] [Abstract] [Full Text] [Related]
6. hsp90 is a potential risk factor for ovarian cancer prognosis: an evidence of a Chinese clinical center.
Duan C; Li K; Pan X; Wei Z; Xiao L
BMC Cancer; 2023 May; 23(1):489. PubMed ID: 37259027
[TBL] [Abstract] [Full Text] [Related]
7. Mass Spectrometry-Based Proteomics of Epithelial Ovarian cancers: A Clinical Perspective.
Qian L; Sun R; Xue Z; Guo T
Mol Cell Proteomics; 2023 Jul; 22(7):100578. PubMed ID: 37209814
[TBL] [Abstract] [Full Text] [Related]
8. hsp90aB1 as the Druggable Target of Maggot Extract Reverses Cisplatin Resistance in Ovarian cancer.
Wang D; Tang X; Ruan J; Zhu Z; Wang R; Weng Y; Zhang Y; Wang T; Huang Y; Wang H; Su Z; Wu X; Tao G; Wang Y
Oxid Med Cell Longev; 2023; 2023():9335440. PubMed ID: 37180757
[TBL] [Abstract] [Full Text] [Related]
9. Silibinin, an hsp90 Inhibitor, on Human ACTH-Secreting Adenomas.
Pecori Giraldi F; Cassarino MF; Sesta A; Lasio G; Losa M
Neuroendocrinology; 2023; 113(6):606-614. PubMed ID: 36791678
[TBL] [Abstract] [Full Text] [Related]
10. Single-Cell Dissection of the Multiomic Landscape of High-Grade Serous Ovarian cancer.
Wang Y; Xie H; Chang X; Hu W; Li M; Li Y; Liu H; Cheng H; Wang S; Zhou L; Shen D; Dou S; Ma R; Mao Y; Zhu H; Zhang X; Zheng Y; Ye X; Wen L; Kee K; Cui H; Tang F
Cancer Res; 2022 Nov; 82(21):3903-3916. PubMed ID: 35969151
[TBL] [Abstract] [Full Text] [Related]
11. Role of surgery to the primary tumor in metastatic anaplastic thyroid carcinoma: pooled analysis and SEER-based study.
Oliinyk D; Augustin T; Rauch J; Koehler VF; Belka C; Spitzweg C; Käsmann L
J Cancer Res Clin Oncol; 2023 Jul; 149(7):3527-3547. PubMed ID: 35960373
[TBL] [Abstract] [Full Text] [Related]
12. Hyperthermic intraperitoneal chemotherapy (HIPEC) with carboplatin induces distinct transcriptomic changes in ovarian tumor and normal tissues.
Moukarzel LA; Ferrando L; Dopeso H; Stylianou A; Basili T; Pareja F; Da Cruz Paula A; Zoppoli G; Abu-Rustum NR; Reis-Filho JS; Long Roche K; Tew WP; Chi DS; Sonoda Y; Zamarin D; Aghajanian C; O'Cearbhaill RE; Zivanovic O; Weigelt B
Gynecol Oncol; 2022 May; 165(2):239-247. PubMed ID: 35292180
[TBL] [Abstract] [Full Text] [Related]
13. Lamin-A interacting protein hsp90 is required for DNA damage repair and chemoresistance of ovarian cancer cells.
Wang Y; Chen Q; Wu D; Chen Q; Gong G; He L; Wu X
Cell Death Dis; 2021 Aug; 12(8):786. PubMed ID: 34381017
[TBL] [Abstract] [Full Text] [Related]
14. Molecular Chaperones and Thyroid cancer.
Paladino L; Vitale AM; Santonocito R; Pitruzzella A; Cipolla C; Graceffa G; Bucchieri F; Conway de Macario E; Macario AJL; Rappa F
Int J Mol Sci; 2021 Apr; 22(8):. PubMed ID: 33919591
[TBL] [Abstract] [Full Text] [Related]
15. Hypochlorous acid selectively promotes toxicity and the expression of danger signals in human abdominal cancer cells.
Freund E; Miebach L; Stope MB; Bekeschus S
Oncol Rep; 2021 May; 45(5):. PubMed ID: 33760187
[TBL] [Abstract] [Full Text] [Related]
16. Regulation of the EGFR Pathway by hsp90 Is Involved in the Pathogenesis of Cushing's Disease.
Shen Y; Ji C; Jian X; Zhou J; Zhang Q; Qiao N; Zhang Y; Shou X; Zhou X; Ma Z
Front Endocrinol (Lausanne); 2020; 11():601984. PubMed ID: 33537004
[TBL] [Abstract] [Full Text] [Related]
17. hsp90 identified by a proteomic approach as druggable target to reverse platinum resistance in ovarian cancer.
Lombardi R; Sonego M; Pucci B; Addi L; Iannelli F; Capone F; Alfano L; Roca MS; Milone MR; Moccia T; Costa A; Di Gennaro E; Bruzzese F; Baldassarre G; Budillon A
Mol Oncol; 2021 Apr; 15(4):1005-1023. PubMed ID: 33331136
[TBL] [Abstract] [Full Text] [Related]
18. Unbiased in vivo preclinical evaluation of anticancer drugs identifies effective therapy for the treatment of pancreatic adenocarcinoma.
Grbovic-Huezo O; Pitter KL; Lecomte N; Saglimbeni J; Askan G; Holm M; Melchor JP; Chandwani R; Joshi S; Haglund C; Iacobuzio-Donahue CA; Chiosis G; Tammela T; Leach SD
Proc Natl Acad Sci U S A; 2020 Dec; 117(48):30670-30678. PubMed ID: 33199632
[TBL] [Abstract] [Full Text] [Related]
19. Priming with HDAC Inhibitors Sensitizes Ovarian cancer Cells to treatment with Cisplatin and hsp90 Inhibitors.
Rodrigues Moita AJ; Bandolik JJ; Hansen FK; Kurz T; Hamacher A; Kassack MU
Int J Mol Sci; 2020 Nov; 21(21):. PubMed ID: 33167494
[TBL] [Abstract] [Full Text] [Related]
20. Loss of ARID1A Promotes Epithelial-Mesenchymal Transition and Sensitizes Pancreatic Tumors to Proteotoxic Stress.
Tomihara H; Carbone F; Perelli L; Huang JK; Soeung M; Rose JL; Robinson FS; Lissanu Deribe Y; Feng N; Takeda M; Inoue A; Poggetto ED; Deem AK; Maitra A; Msaouel P; Tannir NM; Draetta GF; Viale A; Heffernan TP; Bristow CA; Carugo A; Genovese G
Cancer Res; 2021 Jan; 81(2):332-343. PubMed ID: 33158812
[TBL] [Abstract] [Full Text] [Related]
[Next]
